The American Journal of Managed Care17 天
Phase 3 STEER Study of SMA Gene Therapy Meets Primary End Point
Intrathecal onasemnogene abeparvovec improved HFMSE scores in patients with SMA type 2, indicating enhanced motor function. The STEER study confirmed the therapy's favorable safety profile ...